Annual Working Capital
$189.62 M
-$60.70 M-24.25%
December 31, 2023
Summary
- As of February 7, 2025, GLUE annual working capital is $189.62 million, with the most recent change of -$60.70 million (-24.25%) on December 31, 2023.
- During the last 3 years, GLUE annual working capital has risen by +$175.30 million (+1224.53%).
- GLUE annual working capital is now -42.89% below its all-time high of $332.03 million, reached on December 31, 2021.
Performance
GLUE Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Working Capital
$209.57 M
-$25.98 M-11.03%
September 30, 2024
Summary
- As of February 7, 2025, GLUE quarterly working capital is $209.57 million, with the most recent change of -$25.98 million (-11.03%) on September 30, 2024.
- Over the past year, GLUE quarterly working capital has increased by +$51.82 million (+32.85%).
- GLUE quarterly working capital is now -41.43% below its all-time high of $357.78 million, reached on September 30, 2021.
Performance
GLUE Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Working Capital Formula
Working Capital = Current Assets − Current Liabilities
GLUE Working Capital Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -24.3% | +32.9% |
| 3 y3 years | +1224.5% | -16.3% |
| 5 y5 years | +3368.4% | -16.3% |
GLUE Working Capital Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -42.9% | at low | -36.9% | +32.9% |
| 5 y | 5-year | -42.9% | +3368.4% | -41.4% | +1363.9% |
| alltime | all time | -42.9% | +3368.4% | -41.4% | +1363.9% |
Monte Rosa Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $209.57 M(-11.0%) |
| Jun 2024 | - | $235.55 M(+49.3%) |
| Mar 2024 | - | $157.74 M(-16.8%) |
| Dec 2023 | $189.62 M(-24.2%) | $189.62 M(+18.3%) |
| Sep 2023 | - | $160.30 M(-15.2%) |
| Jun 2023 | - | $189.01 M(-14.1%) |
| Mar 2023 | - | $220.04 M(-12.1%) |
| Dec 2022 | $250.32 M | $250.32 M(-8.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $273.44 M(-3.1%) |
| Jun 2022 | - | $282.27 M(-8.3%) |
| Mar 2022 | - | $307.88 M(-7.3%) |
| Dec 2021 | $332.03 M(+2219.3%) | $332.03 M(-7.2%) |
| Sep 2021 | - | $357.78 M(+3.0%) |
| Jun 2021 | - | $347.50 M(+113.7%) |
| Mar 2021 | - | $162.62 M(+1035.9%) |
| Dec 2020 | $14.32 M(+161.9%) | $14.32 M |
| Dec 2019 | $5.47 M | - |
FAQ
- What is Monte Rosa Therapeutics annual working capital?
- What is the all time high annual working capital for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual working capital year-on-year change?
- What is Monte Rosa Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly working capital year-on-year change?
What is Monte Rosa Therapeutics annual working capital?
The current annual working capital of GLUE is $189.62 M
What is the all time high annual working capital for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual working capital is $332.03 M
What is Monte Rosa Therapeutics annual working capital year-on-year change?
Over the past year, GLUE annual working capital has changed by -$60.70 M (-24.25%)
What is Monte Rosa Therapeutics quarterly working capital?
The current quarterly working capital of GLUE is $209.57 M
What is the all time high quarterly working capital for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly working capital is $357.78 M
What is Monte Rosa Therapeutics quarterly working capital year-on-year change?
Over the past year, GLUE quarterly working capital has changed by +$51.82 M (+32.85%)